SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Large B-cell lymphoma expressing the ALK kinase and lacking the t(2;5) translocation
This is a neoplasm of ALK-positive monomorphic large immunoblast-like B cells, sometimes with plasmablastic differentiation. This lymphoma is very rare (<1% of DLBCL) with less than 40 cases reported to date.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see code 9684/3.)
Most patients present with Stage III/IV. Because these tumors are negative for CD20 antigen, they are insensitive to rituximab.